This content is machine translated ESC guidelines on heart failure These are the new recommendations Numerous studies published in the last two years made it necessary to update the 2021 ESC Heart Failure Guidelines. In particular, this refers to new studies on SGLT2 inhibitors in…
View Post 2 min This content is machine translated SGLT2 inhibitor convinces Dapagliflozin may score well in nephro- and cardioprotection Patients with diabetic nephropathy can now be effectively treated with SGLT2 inhibitors. They are also said to have cardioprotective effects. Dapagliflozin is now the first and only antidiabetic agent approved…
View Post 4 min This content is machine translated Heart failure SGLT2 inhibitors – are the new preparations more than just good antidiabetic agents? SGLT2 inhibitors have been used successfully for some time in the treatment of diabetes mellitus. They are associated with effective blood glucose lowering through increased renal glucose excretion. But they…
View Post 7 min This content is machine translated Chronic renal failure Nephroprotection – progress at last! Nephroprotection includes interventions that slow GFR decline over time, thereby delaying end-stage renal failure. The most recent intervention is the use of SGLT2 inhibitors in patients with diabetic nephropathy.
View Post 9 min This content is machine translated New antidiabetic agents Combination therapies enable very potent HbA1c reduction Lifestyle modification (exercise, diet) and metformin remain the cornerstones in the treatment of diabetes mellitus type 2. Before initiating antidiabetic therapy, it is recommended to set an individual HbA1c target. Advantages…
